Himension Capital Singapore PTE. LTD. lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 29.3% during the 1st quarter, HoldingsChannel reports. The fund owned 13,169 shares of the biopharmaceutical company’s stock after acquiring an additional 2,984 shares during the period. Himension Capital Singapore PTE. LTD.’s holdings in Alnylam Pharmaceuticals were worth $4,357,000 at the end of the most recent quarter.
Several other hedge funds have also modified their holdings of ALNY. Andra AP fonden grew its holdings in Alnylam Pharmaceuticals by 78.6% in the first quarter. Andra AP fonden now owns 86,697 shares of the biopharmaceutical company’s stock valued at $28,685,000 after purchasing an additional 38,157 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Alnylam Pharmaceuticals by 27.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 384,205 shares of the biopharmaceutical company’s stock valued at $127,071,000 after purchasing an additional 82,340 shares during the last quarter. Parallel Advisors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 7.9% in the 1st quarter. Parallel Advisors LLC now owns 891 shares of the biopharmaceutical company’s stock valued at $295,000 after purchasing an additional 65 shares during the last quarter. AlphaCentric Advisors LLC grew its stake in shares of Alnylam Pharmaceuticals by 5.8% during the 1st quarter. AlphaCentric Advisors LLC now owns 1,370 shares of the biopharmaceutical company’s stock valued at $453,000 after buying an additional 75 shares during the period. Finally, SEB Asset Management AB purchased a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter valued at $9,977,000. 92.97% of the stock is owned by institutional investors and hedge funds.
Alnylam Pharmaceuticals Stock Down 0.5%
Shares of Alnylam Pharmaceuticals stock opened at $271.37 on Wednesday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $266.27 and a twelve month high of $495.55. The stock has a market cap of $36.23 billion, a price-to-earnings ratio of 74.14 and a beta of 0.27. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. The company has a fifty day moving average price of $293.50 and a 200 day moving average price of $318.80.
Insider Activity
In other news, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the sale, the director owned 1,582 shares in the company, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.86% of the company’s stock.
Analysts Set New Price Targets
Several research analysts recently weighed in on the company. Wall Street Zen lowered Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 7th. Citigroup initiated coverage on Alnylam Pharmaceuticals in a report on Tuesday, May 19th. They issued a “buy” rating and a $380.00 target price on the stock. Morgan Stanley boosted their price target on Alnylam Pharmaceuticals from $370.00 to $400.00 and gave the company an “equal weight” rating in a research report on Friday, July 10th. Bank of America cut their price objective on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a report on Tuesday, July 14th. Finally, Truist Financial decreased their target price on Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating for the company in a report on Monday, July 13th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $455.31.
Read Our Latest Stock Report on Alnylam Pharmaceuticals
Alnylam Pharmaceuticals Profile
Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.
Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.
Featured Stories
- Five stocks we like better than Alnylam Pharmaceuticals
- Confidence Is Back, But Earnings Show the Consumer Is Being Picky
- AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off
- 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative?
- 3 Photonics Companies Making Quantum Tech Possible
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
